Hyperlipemia
11
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
27%
3 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
Veteran Peer Coaches Optimizing and Advancing Cardiac Health
To Evaluate the Efficacy and Safety of JS002 in HoFH Patients
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
Safety and Tolerability of SHR-1918 in Healthy Subjects
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia
A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..
Effect of Rosuvastatin Therapy on HDL2 Level